Variorelix (Ganirelix), a newly developed infertility treatment drug, was officially unveiled at the 11th International Congress on Reproductive Medicine and the 6th International Congress on Reproductive Genetics, held from May 15–17, 2025 (25–27 Ordibehesht 1404) at Shahid Sadoughi Hospital in Yazd, Iran.
According to the Public Relations department of Golrang Pharmaceutical Group, the product was developed and manufactured by Varian Pharmed, a knowledge-based subsidiary of the Golrang Pharmaceutical Group. Variorelix is a 250-microgram GnRH antagonist injection designed specifically to support infertility treatment in women, marking a significant addition to Golrang’s growing reproductive health portfolio.
A New Generation of Fertility Medication
Variorelix belongs to the GnRH antagonist class of medications, which precisely regulate sex hormone levels to optimize ovulation timing. Compared to traditional agonist-based treatments, GnRH antagonists offer advantages such as shorter treatment duration, lower risk of ovarian hyperstimulation syndrome (OHSS), and greater flexibility in IVF protocols, thereby improving the success rate and safety of assisted reproduction treatments.
Innovative Pre-Filled Syringe Technology
Variorelix is formulated using advanced PFS (pre-filled syringe) technology, which significantly reduces the risk of contamination, dosing errors, and injection-related complications. This ready-to-use format ensures ease of use for patients and medical professionals alike. Additionally, the drug’s room-temperature stability facilitates its transportation and nationwide accessibility, particularly in remote areas with limited refrigeration infrastructure.
Local Production, Global Standards
This is the first time Variorelix has been fully manufactured domestically in Iran. Previously, similar imported products were sold at approximately around 14 USD. However, mass production will make Variorelix available at 40% lower cost compared to its international counterparts, offering both economic and therapeutic advantages to Iranian patients.
In its first year of release, Varian Pharmed is expected to supply 50% of the national demand, with plans to increase this capacity to 90% by the second year of production.
Advancing Pharmaceutical Self-Reliance
The congress brought together Iranian and international experts to foster knowledge exchange and promote clinical advancements in reproductive medicine. The active participation of knowledge-based companies such as Varian Pharmed demonstrates the high scientific and industrial potential of Iran’s pharmaceutical sector and represents a significant step toward national self-sufficiency in the production of advanced medications.
